Xenon Seven

Talent Acquisition & Human Resources Coordinator

Vancouver · Director

Work authorization requiredDetected 39 days ago

RESTExcelRecruitingHRPerformance ManagementHRISClinical TrialsCommunicationCollaborationTime ManagementMicrosoft Office

About the role

We are seeking a Talent Acquisition & Human Resources Coordinator to join the HR Operations team.
This role will be primarily supporting a high volume of full-cycle recruitment coordination and will have the opportunity to work with various hiring managers, HRBPs and Talent Acquisition team members in delivering an exceptional candidate experience.
This is an exciting opportunity for an individual who is process-driven, has exceptional attention to detail, and can efficiently juggle a variety of operational activities.

Responsibilities

Manage core recruiting operations tasks, including job approvals, job postings, and employment agreement preparation.
Coordinate closely with hiring managers and interviewers to align availability, manage schedule changes, and proactively communicate updates.
Support Xenon's student programs with hiring managers and local post-secondary institutions, as applicable.
Support projects and deliverables to support Workday systems implementation, as needed.

Requirements

Bachelor's degree in Business Administration with a specialization in Human Resources Management is desired.
Experience managing high-volume recruiting coordination, including coordinating complex schedules across multiple interviewers.
2-4 years of Human Resources experience in an operational and administrative capacity in a fast-paced environment.
Previous experience with Workday is required
Strong operational discipline - proactive and organized, with a strong track record of delivering high quality results.
Ability to multi-task, propose and establish priorities in accordance with company objectives.
Facilitate background & reference checks and manage associated documentation and all vendor coordination as required.
Collaborate with the Payroll team to ensure timely submission of HR information as required.
Excellent computer and software skills, specifically with Microsoft products (Outlook, Teams, Word, Excel, PowerPoint) and SharePoint. High aptitude for learning new technology is preferred.
Dayforce (Core, Onboarding, Recruitment) or Ashby is an asset.
Excellent prioritization and time management skills.
Excellent verbal, written and presentation skills.
Process oriented with a high attention to detail.
Demonstrates maturity and sound judgment
able to manage sensitive information/situations in a professional and confidential manner.

Nice to have

Knowledge of and experience with Canadian and US employment, human rights, privacy and immigration laws is preferred.

Skills

Stay up to date with relevant training and processes for relevant systems and tools that Xenon utilizes.
Provide clear information and explanations to employees regarding established and routine human resource programs, policies, and procedures.
Conduct all behavior in a professional and respectful manner while maintaining confidentiality.
Conduct work with a high level of accuracy and quality; proactively seeking ways for process improvements and streamlining.
Other duties as assigned.

Compensation

Coordinate employee life-cycle activities including but not limited to tracking annual objectives and performance management activities, drafting employee change forms and letters, compensation administration, and departure letters.

Company info

Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
What We Do:
We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.
Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

Visa & Work Authorization

Coordinate onboarding activities, including scheduling pre-arrival communication with new hires, supporting hiring managers with the Manager Checklist, arranging Corporate Orientation schedules with internal trainers, administrating appli

Apply directly at Xenon Seven →Create a free account for alerts like this View Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.